Brought to you by 
TG Therapeutics completes reverse merger; raises $25mm privately
08 Mar 2012
Executive Summary
TG Therapeutics Inc. (cancer and autoimmune drug development) has raised $25mm through the private sale of 277.3mm common shares at $0.09 each. Investors also received five-year warrants to purchase 156mm shares at $0.04. The closing of the tranched placement is concurrent with TG's licensing exclusive rights to LFB Biotechnologies's CD20-targeting MAb Utuxin. TG recently reverse merged with Manhattan Pharmaceuticals, to gain that company's public status. Manhattan now operates under the TG Therapeutics name.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Private Investment in Public Equity
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
TG Therapeutics completes reverse merger; raises $25mm privately
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice